ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,431.60
      -0.04%
      US Tech 100
      19,168.00
      0.52%
      Dow Jones
      38,589.16
      -0.15%
      Brent Oil
      82.275
      0.00%
      Bitcoin
      66,044.69
      0.06%
      Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Outlook Therapeutics Inc (OTLKW)

      7. Outlook Therapeutics Inc (OTLKW) News

      OTLKW

      Outlook Therapeutics (OTLKW)

      Outlook Therapeutics Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:OTLKW
      DateTimeSourceHeadlineSymbolCompany
      06/11/20249:05AMGlobeNewswire Inc.Outlook Therapeutics® to Present at the Virtual Investor Pitch ConferenceNASDAQ:OTLKWOutlook Therapeutics Inc
      05/28/20248:05AMGlobeNewswire Inc.Outlook Therapeutics® Receives European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMDNASDAQ:OTLKWOutlook Therapeutics Inc
      05/15/20245:00PMGlobeNewswire Inc.Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2024 and Provides Corporate UpdateNASDAQ:OTLKWOutlook Therapeutics Inc
      05/13/20248:50AMGlobeNewswire Inc.Outlook Therapeutics® Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMDNASDAQ:OTLKWOutlook Therapeutics Inc
      05/09/20248:45AMGlobeNewswire Inc.Outlook Therapeutics® to Report Financial Results for Second Quarter Fiscal Year 2024 on May 16, 2024 and Host Inaugural Quarterly Conference Call and WebcastNASDAQ:OTLKWOutlook Therapeutics Inc
      05/02/20249:05AMGlobeNewswire Inc.Outlook Therapeutics® to Present at the Retina World Congress 2024NASDAQ:OTLKWOutlook Therapeutics Inc
      04/29/20249:00AMGlobeNewswire Inc.Outlook Therapeutics® to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation ShowcaseNASDAQ:OTLKWOutlook Therapeutics Inc
      04/15/20244:15PMGlobeNewswire Inc.Outlook Therapeutics® Announces Closing of Private Placement of $5.0 MillionNASDAQ:OTLKWOutlook Therapeutics Inc
      03/22/20247:35AMGlobeNewswire Inc.Outlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMDNASDAQ:OTLKWOutlook Therapeutics Inc
      03/18/20245:10PMGlobeNewswire Inc.Outlook Therapeutics® Announces Closing of Private Placement of up to $159 MillionNASDAQ:OTLKWOutlook Therapeutics Inc
      03/12/20248:05AMGlobeNewswire Inc.Outlook Therapeutics® Announces Effective Date for 1-for-20 Reverse Stock SplitNASDAQ:OTLKWOutlook Therapeutics Inc
      02/14/20248:05AMGlobeNewswire Inc.Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2024 and Provides Corporate UpdateNASDAQ:OTLKWOutlook Therapeutics Inc
      01/31/20248:05AMGlobeNewswire Inc.Outlook Therapeutics® Doses First Subject in NORSE EIGHTNASDAQ:OTLKWOutlook Therapeutics Inc
      01/23/20248:00AMGlobeNewswire Inc.Outlook Therapeutics® Receives FDA Agreement Under Special Protocol Assessment (SPA) for 90 Day Non-Inferiority Study, NORSE EIGHT, and Announces Private Placement of Up to $172 Million to Advance ONS-5010NASDAQ:OTLKWOutlook Therapeutics Inc
      12/22/20238:05AMGlobeNewswire Inc.Outlook Therapeutics® Reports Financial Results for Fiscal Year 2023 and Reiterates ONS-5010 Clinical and Regulatory Path Forward in the U.S. and EUNASDAQ:OTLKWOutlook Therapeutics Inc
      12/19/20238:05AMGlobeNewswire Inc.Outlook Therapeutics® Submits Special Protocol Assessment (SPA) to FDA for Non-Inferiority Study of ONS-5010NASDAQ:OTLKWOutlook Therapeutics Inc
      12/06/20238:05AMGlobeNewswire Inc.Outlook Therapeutics® Announces Strategic Organizational RealignmentNASDAQ:OTLKWOutlook Therapeutics Inc
      11/27/20238:05AMGlobeNewswire Inc.Outlook Therapeutics® Announces Receipt of Type A Meeting Minutes and Reiterates Regulatory Path Forward for ONS-5010NASDAQ:OTLKWOutlook Therapeutics Inc
      11/14/20238:05AMGlobeNewswire Inc.Outlook Therapeutics® Adds Global Commercial Expertise with Appointment of Jedd Comiskey as Senior VP - Head of EuropeNASDAQ:OTLKWOutlook Therapeutics Inc
      11/02/20238:05AMGlobeNewswire Inc.Outlook Therapeutics® Provides Update on Type A Meetings with FDANASDAQ:OTLKWOutlook Therapeutics Inc
      11/01/20238:05AMGlobeNewswire Inc.Outlook Therapeutics® to Present at Guggenheim’s 5th Annual Inflammation, Neurology & Immunology (INI) ConferenceNASDAQ:OTLKWOutlook Therapeutics Inc
      09/29/20238:05AMGlobeNewswire Inc.Outlook Therapeutics® Requests Type A Meeting With FDANASDAQ:OTLKWOutlook Therapeutics Inc
      09/21/20238:05AMGlobeNewswire Inc.Outlook Therapeutics® to Present at the 2023 Cantor Fitzgerald Global Healthcare ConferenceNASDAQ:OTLKWOutlook Therapeutics Inc
      09/05/20238:05AMGlobeNewswire Inc.Outlook Therapeutics® to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:OTLKWOutlook Therapeutics Inc
      08/30/20236:00AMGlobeNewswire Inc.Outlook Therapeutics® Provides Regulatory Update on FDA Review of ONS-5010 / LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMDNASDAQ:OTLKWOutlook Therapeutics Inc
      08/14/20238:05AMGlobeNewswire Inc.Outlook Therapeutics® Reports Financial Results for Third Quarter Fiscal Year 2023 and Reiterates Key Anticipated Near-Term MilestonesNASDAQ:OTLKWOutlook Therapeutics Inc
      08/01/20238:45AMGlobeNewswire Inc.Outlook Therapeutics® to Present at the BTIG Virtual Biotechnology Conference 2023NASDAQ:OTLKWOutlook Therapeutics Inc
      05/16/20237:10AMEdgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:OTLKWOutlook Therapeutics Inc
      05/16/20236:06AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:OTLKWOutlook Therapeutics Inc
      05/15/20234:51PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:OTLKWOutlook Therapeutics Inc
       Showing the most relevant articles for your search:NASDAQ:OTLKW